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Abstract
Objective Quantitative estimates of air pollution health
impacts have become an increasingly critical input to
policy decisions. The WHO project ‘‘Health risks of air
pollution in Europe—HRAPIE’’ was implemented to pro-
vide the evidence-based concentration–response functions
for quantifying air pollution health impacts to support the
2013 revision of the air quality policy for the European
Union (EU).
Methods A group of experts convened by WHO Regional
Office for Europe reviewed the accumulated primary
research evidence together with some commissioned re-
views and recommended concentration–response functions
for air pollutant–health outcome pairs for which there was
sufficient evidence for a causal association.
Results The concentration–response functions link sev-
eral indicators of mortality and morbidity with short- and
long-term exposure to particulate matter, ozone and nitro-
gen dioxide. The project also provides guidance on the use
of these functions and associated baseline health informa-
tion in the cost–benefit analysis.
Conclusions The project results provide the scientific
basis for formulating policy actions to improve air quality
and thereby reduce the burden of disease associated with
air pollution in Europe.
Keywords Air pollutants  Health impact assessment 
Cost–benefit analysis  Particulate matter  Ozone 
Nitrogen dioxide
Introduction
In 2013, WHO Regional Office for Europe coordinated two
international projects: ‘‘Review of evidence on health
aspects of air pollution—REVIHAAP’’ and ‘‘Health risks
of air pollution in Europe—HRAPIE’’ in order to provide
the European Commission (EC) and its stakeholders with
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evidence-based advice on the health aspects of air pollution
for the review of the EU air quality policies. This advice
was grounded in a review of the latest scientific evidence
on the health effects of air pollutants and involved a large
group of invited experts. The projects addressed a list of 26
key policy-relevant questions posed by the EC (WHO
Regional office for Europe 2013a, b) and covering specific
topics concerning health aspects of individual air pollutants
and general aspects important to air quality management.
Results of the REVIHAAP project provided an essential
input to the HRAPIE project for which the task was to
answer the following question: ‘‘What concentration–re-
sponse functions for key pollutants should be included in
cost–benefit analysis supporting the revision of EU air
quality policy?’’
Methods of air pollution health risk assessment have
been well established in Europe since the first European
project (Ku¨nzli et al. 2000) and adopted in many global
projects including the first global burden of disease (GBD)
study (Cohen et al. 2005; Lopez 2013) and the 2010 GBD
update (Burnett et al. 2014; Lim et al. 2012). Concentra-
tion–response functions (CRFs) are necessary elements for
the quantification of health impacts due to air pollution and
require regular evaluation and update to incorporate new
developments in science. In the specific case of the
HRAPIE project, the CRFs were recommended for the
quantification of impacts resulting from policies designed
to reduce pollution concentrations. The recommended
CRFs were subsequently used to identify the pollution re-
duction strategies that will most effectively deliver a
benefit to health as part of the cost-effectiveness analysis
(IIASA 2013). The impacts were monetized and then
compared with the costs of interventions to form a cost–
benefit analysis that enabled evidence-based policy making
(Holland 2014). The HRAPIE project recommended the
CRFs linking particulate matter (PM), ozone (O3) and ni-
trogen dioxide (NO2) concentrations with specific health
effects and provided rationale for the decisions. In addition,
the project indicated the background health data required
for the quantification of effects. As well, the project rec-
ommended approaches to integrate specific health
outcomes into the estimation of the total health burden of
the exposure. The full results of the HRAPIE project are
available in the project report (WHO Regional Office for
Europe 2013b). The present paper provides a summary of
the HRAPIE recommendations and a discussion on their
implementation in the EC air policy package, which pro-
poses a package of measures to reduce air pollution with a
view of reducing impacts on human health and the envi-
ronment in the EU.
Methods
Development process for HRAPIE project
recommendations
We agreed to apply the established methods of air pollution
health impact assessment as used and adapted in previous
projects (Burnett et al. 2014; Cohen et al. 2005; Ku¨nzli
et al. 2000; Lim et al. 2012). The focus of the methods was
on the recommendation of CRFs. The discussions at WHO
expert meetings provided general direction for the work on
CRFs linking particulate matter with an aerodynamic di-
ameter smaller than 2.5 lm (PM2.5) and O3 with mortality
in cost-effectiveness analysis, as well as for the other
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outcomes to be considered for PM, O3 and NO2 in the cost–
benefit analysis. Invited external reviewers selected to
represent a range of countries and relevant disciplines also
provided detailed comments on a draft version of the
project report. The experts used the discussions from
meetings and external reviewers’ comments to finalize the
project conclusions.
Where available, recent systematic reviews or meta-
analyses of epidemiological studies were used as input to
the HRAPIE project (Hoek et al. 2012, 2013; Katsouyanni
et al. 2009; Samoli et al. 2006; Weinmayr et al. 2010;
WHO Regional Office for Europe 2013a). In some other
cases, a dedicated meta-analysis was performed within the
scope of the HRAPIE project, based on information col-
lated by the Air Pollution Epidemiology Database (APED)
at St. George’s, University of London (Anderson et al.
2007). This database contains details and results from all
time-series studies of mortality and hospital admissions
indexed in Medline, Embase, and Web of Knowledge until
May 2011. Formal systematic reviews of the evidence were
not available or feasible for all issues considered by
HRAPIE, due to the limited resources of the project.
Therefore, a few of the recommendations were formulated
without a formal systematic review (such as for the effects
of long-term PM10 exposure on postneonatal mortality and
on incidence of chronic bronchitis in adults).
Implementation of the HRAPIE project
recommendations
The HRAPIE project provided recommendations for CRFs
for which there is sufficient evidence for causality of as-
sociations according to the prior REVIHAAP project
conclusions. It focussed on those air pollutants observed at
concentrations causing health concerns, and which could
be estimated at an appropriate spatial scale across Europe
for the modelling of impacts. Each of the pollutant–out-
come pairs recommended for cost–benefit analysis was
classified into two categories:
• Group A: pollutant–outcome pairs for which enough
data are available to enable quantification of effects;
• Group B: pollutant–outcome pairs for which there is
more uncertainty about the data used for quantification
of effects.
More information on the classification scheme is pro-
vided in the Online Resource. The recommendations
considered specific conditions in EU countries—par-
ticularly in relation to the range of PM, O3 and NO2
concentrations expected to be observed in the EU in
2020—as well as the availability of baseline health data.
Therefore, for the analysis in EU, no extrapolation beyond
the range covered by epidemiological studies on the effects
of ambient PM, O3 or NO2 was needed. However, gener-
alization of the recommended approaches to other regions
of the globe or individual countries, or to particular mix-
tures at the local level, may not be appropriate.
Meta-analyses were generally used to derive the coef-
ficients. The random-effects model used in many meta-
analyses makes no prior assumption of the homogeneity in
distribution around the mean coefficient. The CIs associ-
ated with the recommended CRFs quantified the random
error and the variability attributed to heterogeneity in the
epidemiologic effect estimates used for health impact
assessment; this is only a part of the total uncertainty in the
risk estimates produced by the health impact assessment
and cost–benefit analysis processes. Additional uncertain-
ties were associated with other aspects of the overall
process—for example, in the measurement and modelling
of pollution, the estimates of background rates for mor-
bidity or mortality and monetary valuation (WHO Regional
Office for Europe 2013b; Holland 2014). Some less tan-
gible issues arose from: (1) the transferability to the EU as
a whole of CRFs and background rates from the locations
where studies were carried out; (2) agreeing what particular
pollutant–outcome pairs should be used together to esti-
mate the health impacts of particular policies and
measures; and (3) assessing the uncertainty of an overall
estimate of effects, aggregated (after conversion to mone-
tary values) over the various pollutant–outcome pairs.
An effort was made to give the best evidence-based
estimate of the relationship between the pollutant and that
health outcome for each pollutant–outcome pair included.
However, some assumptions made by the experts might
lead to underestimation of the effects. For example, acute
effects of air pollution can occur with a delay (lag) of a few
days to weeks but in selecting risk coefficients linking
short-term exposures to health outcomes; however, the
distributed lags were not taken into account, possibly re-
sulting in underestimation of the overall effect. In addition,
some health outcomes, such as low birth weight or lung
function, for which there is evidence of air pollution effects
were excluded because of difficulties in attaching monetary
values. Further, the use of the limited set of CRFs proposed
in Group A rather than the full set of CRFs may lead to
underestimation of effect, as there is sufficient evidence of
a causal relationship for pollutant–outcome pairs in both
groups.
Possible double counting of effects of various
pollutants
Some of the effects of a pollutant on one health outcome
may be captured in an estimate of effect on another health
outcome or their group (e.g. mortality due to a specific
cause is a part of all-cause mortality). To minimize double
Quantifying the health impacts of ambient air pollutants… 621
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counting in the calculation of the total costs and benefits for
a pollutant, we proposed a set of rules. We identified with
an asterisk (*) those effect estimates that contributed to the
total cost and benefits (and assumed that their effects are
additive) in either the limited set (Group A*) or the ex-
tended set (Group B*) of effects. Those without the asterisk
were considered to reflect the effects already accounted for
by summing those with the asterisk.
Quantification of the health impacts of air pollution in
the HRAPIE project focuses on three pollutants: PM
(PM2.5, PM10) O3 and NO2. In the ambient air, those pol-
lutants are usually correlated to some extent—sometimes
negatively so, as with O3 and PM10 in winter (Katsouyanni
et al. 2009). The REVIHAAP project therefore proposed
quantification of health effects associated with these pol-
lutants only after adjustment for at least one of the others
(WHO Regional Office for Europe 2013a). Far fewer
studies systematically applying two- or multi-pollutant
modelling are available, however, than studies using sin-
gle-pollutant models. Furthermore, effect estimates for a
given pollutant derived from a multi-pollutant model may
be subject to bias if the pollutants are correlated with each
other and subject to measurement error (Fung and Krewski
1999). This can lead to underestimation of the RR for a
pollutant of interest.
In balancing these considerations, the HRAPIE project
generally opted for effect estimates based on the largest
possible group of studies—i.e. reporting single-pollutant
analyses—for quantification. Quantification of the impact
for one pollutant from single-pollutant models may there-
fore include effects attributable to another with which it is
correlated. Consequently, for any particular health outcome
and exposure period (long-term or short-term exposure),
estimated impacts of the three individual pollutants should
not be added without recognizing that this will, in most
practical circumstances, lead to some overestimation of the
true impact. Impacts estimated for one pollutant only will,
on the other hand, underestimate the true impact of the
pollution mixture, if other pollutants affect that same health
outcome independently.
Results
The HRAPIE experts recommended CRFs linking long and
short-term exposure to PM, O3 and NO2 with several indi-
cators of mortality and morbidity (Table 1). Essential
information concerning the CRFs, their sources and back-
ground health data necessary for estimation of health effects
are provided in Table S1 in the Online Resource. Rationale
for the selection of the CRFs and discussion of their
uncertainties are presented in the full report of the HRAPIE
project (WHO Regional Office for Europe 2013b).
Discussion
Since the HRAPIE project report was published, a number
of policy-relevant questions have come to our attention,
raised by readers of the report. The following paragraphs
provide some further perspectives on the HRAPIE rec-
ommendations, in response to the issues raised.
Use of thresholds, lower levels, counterfactuals, etc.,
in quantifying health impacts
The HRAPIE report recommended that quantification of
long-term effects of PM2.5 on mortality be undertaken at all
concentrations, whereas for NO2, quantification was rec-
ommended only above annual mean concentrations
[20 lg/m3. This has raised some confusion.
We point out that following the recommendation for
estimating impacts of PM2.5 down to zero concentrations,
higher impacts are estimated than in the GBD 2010 study
(Lim et al. 2012). This is because the GBD 2010 study
estimated impacts down to a counterfactual concentration
below which—because of a lack of data—the risk could
not be quantified; this counterfactual for ambient air pol-
lution is different than zero and was chosen as an
alternative exposure distribution to which the current ex-
posure distribution is compared (Burnett et al. 2014). The
selection of counterfactual levels for risk factors, including
for ambient particulate air pollution, were informed by: (1)
a counterfactual population distribution of exposure that is
theoretically possible and would result in the lowest
population disease burden—the theoretical minimum risk
exposure distribution (TMRED), and (2) the availability of
convincing evidence supporting a continuous reduction in
risk of disease extending from current levels down to the
counterfactual TMRED (Murray et al. 2012). On this basis,
the TMRED for ambient PM2.5 was defined by a uniform
distribution with lower and upper bounds at the minimum
and 5th percentile of the PM2.5 exposure distribution of the
American Cancer Society (ACS) Cancer Prevention II
cohort study of 5.8 and 8.8 lg/m3, respectively (Krewski
et al. 2009; Lim et al. 2012; Burnett et al. 2014). This
approach assumed that long-term exposure to PM2.5 less
than 5.8 lg/m3 confers no excess risk, and that although
excess risk may extend below the 5th percentile of the
distribution, estimates in that range are statistically unsta-
ble and therefore highly uncertain. Uncertainty from the
counterfactual, the prevalence of exposure, and the expo-
sure–response function was all propagated into the final
risk factor uncertainty, and the final uncertainty reflected
that of the estimated age- and sex-specific mortality rates as
well. For future work under GBD 2013 the same approach
is used but includes information from 9 cohort studies with
minimum exposure concentrations less than or equal to the
622 M.-E. He´roux et al.
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Table 1 Pollutant–health outcome pairs for which HRAPIE project recommends concentration–response functions (modified from WHO
2013b)
Pollutant metric Health outcome Group RR (95 % CI) per 10 lg/m3
PM2.5, annual mean Mortality, all-cause (natural), age 30? years A* 1.062 (1.040–1.083)
PM2.5, annual mean Mortality, cerebrovascular disease (includes stroke),
ischaemic heart disease, COPD and trachea,
bronchus and lung cancer, age 30? years
A GBD 2010 study (IHME 2013)a
PM10, annual mean Postneonatal (age 1–12 months) infant mortality,
all-cause
B* 1.04 (1.02, 1.07)
PM10, annual mean Prevalence of bronchitis in children, age 6–12
(or 6–18) years
B* 1.08 (0.98–1.19)
PM10, annual mean Incidence of chronic bronchitis in adults
(age 18? years)
B* 1.117 (1.040–1.189)
PM2.5, daily mean Mortality, all-cause, all ages A 1.0123 (1.0045–1.0201)
PM2.5, daily mean Hospital admissions, CVDs (including stroke), all
ages
A* 1.0091 (1.0017–1.0166)
PM2.5, daily mean Hospital admissions, respiratory diseases, all ages A* 1.0190 (0.9982–1.0402)
PM2.5, 2-week average,
converted to PM2.5, annual
average
RADs, all ages B** 1.047 (1.042–1.053)
PM2.5, 2-week average,
converted to PM2.5, annual
average
Work days lost, working-age population
(age 20–65 years)
B* 1.046 (1.039–1.053)
PM10, daily mean Incidence of asthma symptoms in asthmatic
children aged 5–19 years
B* 1.028 (1.006–1.051)
O3, summer months
(April–September), average
of daily maximum 8-h
mean over 35 ppb
Mortality, respiratory diseases, age 30? years B 1.014 (1.005–1.024)
O3, daily maximum 8-h mean
over 35 ppb
Mortality, all (natural) causes, all ages A* 1.0029 (1.0014–1.0043)
O3, daily maximum 8-h mean
over 10 ppb
Mortality, all (natural) causes, all ages A 1.0029 (1.0014–1.0043)
O3, daily maximum 8-h mean
over 35 ppb
Mortality, CVDs and respiratory diseases, all ages A CVD: 1.0049 (1.0013–1.0085);
respiratory: 1.0029 (0.9989–1.0070)
O3, daily maximum 8-h mean
over 10 ppb
Mortality, CVDs and respiratory diseases, all ages A CVD: 1.0049 (1.0013–1.0085);
respiratory: 1.0029 (0.9989–1.0070)
O3, daily maximum 8-h mean
over 35 ppb
Hospital admissions, CVDs (excluding stroke) and
respiratory diseases, age 65? years
A* CVD: 1.0089 (1.0050–1.0127);
respiratory: 1.0044 (1.0007–1.0083)
O3, daily maximum 8-h mean
over 10 ppb
Hospital admissions, CVDs (excluding stroke) and
respiratory diseases, age 65? years
A CVD: 1.0089 (1.0050–1.0127);
respiratory: 1.0044 (1.0007–1.0083)
O3, daily maximum 8-h mean
over 35 ppb
MRADs, all ages B* 1.0154 (1.0060–1.0249)
O3, daily maximum 8-h mean
over 10 ppb
MRADs, all ages B 1.0154 (1.0060–1.0249)
NO2, annual mean
over 20 lg/m3
Mortality, all (natural) causes, age 30? years B* 1.055 (1.031–1.080)
NO2, annual mean Prevalence of bronchitic symptoms in asthmatic
children aged 5–14 years
B* 1.021 (0.990–1.060) per
1 lg/m3 change in
annual mean NO2
NO2, daily maximum 1-h mean Mortality, all (natural) causes, all ages A* 1.0027 (1.0016–1.0038)
NO2, daily maximum 1-h mean Hospital admissions, respiratory diseases, all ages A 1.0015 (0.9992–1.0038)
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5th percentile in the ACS, i.e. 8.8 lg/m3. Whenever im-
pacts of policy measures are estimated using the HRAPIE
CRFs, results will not differ greatly from those obtained
using the GBD approach, as for the medium to long term,
concentrations in most, if not all, areas in Europe will not
likely go below 5.8 lg/m3. We also point out that under the
HRAPIE project, due to wider availability of risk estimates
and greater precision of background national data for all-
cause mortality in Europe, natural all-cause mortality was
chosen as the outcome for quantification. This is different
to what was chosen as outcome as part of the GBD project,
where cause-specific mortality was used because patterns
of causes of death vary considerably globally.
The lower limit of 20 lg/m3 (annual) for NO2 was
motivated by reference to the Naess et al. (2007) Norwe-
gian study, and by unpublished analyses of the data
presented in the Cesaroni et al. (2013) paper from Rome.
These studies assessed NO2 effects in single-pollutant
models. The Naess et al. (2007) paper shows a generally
linear relationship between NO2 and mortality, among
71–90 year olds, in the 20–60 lg/m3 range. Figure 1 in
that paper actually shows a steeper CRF in the 0–20 lg/m3
range, with wider confidence intervals due to the smaller
numbers of participants at such low exposures. The Cesa-
roni et al. (2013) paper continued to show a linear decline
below 20 lg/m3, although again with wider confidence
intervals. The evidence presented does not suggest that the
effect is zero at 20 lg/m3, just that the size of the effect is
less certain below 20 lg/m3. We also note that a recent
cohort study conducted among ca. 52,000 adults in
Copenhagen, Denmark (Raaschou-Nielsen et al. 2012) has
shown a significant, almost linear concentration–response
relationship between long-term NO2 concentration (chosen
by the authors as an indicator of urban air pollution
dominated by traffic exhaust) and mortality [for cardio-
vascular disease (CVD), ischemic heart disease and all
causes] throughout the observed range of NO2 concentra-
tions, which in the large majority of subjects was below
20 lg/m3 (minimum 10.5 lg/m3, median 15.1 lg/m3,
maximum 59.6 lg/m3). This study was included in the
Hoek et al. (2013) meta-analysis, but we did not explicitly
consider it when discussing lower limits of quantification
in the HRAPIE project. All-cause mortality increased by
8 % per 10 lg/m3 NO2 long-term exposure at the residence
address in the study by Raaschou-Nielsen et al. (2012), so
slightly more than estimated in the Hoek et al. meta-ana-
lysis. Therefore, the HRAPIE recommendation to calculate
the impacts of long-term NO2 exposure on mortality for
levels over 20 lg/m3, ignoring potential impacts at lower
concentrations, may be too conservative.
Age dependency of CRFs
The HRAPIE report briefly discussed reasons why RRs for
factors such as smoking and CVD decline with age, and
how that might impact calculations. Air pollution studies
have not generally investigated age dependency of RRs in
any detail, but there is some specific information to suggest
that this is also true for relationships between air pollution
and all-cause and cause-specific mortality. Over a 10-year
follow-up period, an analysis of the ACS-1 study (Enstrom
2005) showed a RR for PM2.5 and all-cause mortality twice
as high among subjects aged 43–64 years at baseline than
in subjects aged 65–99 years at baseline (Table 6 of the
paper). The study by Naess et al. (2007) showed, for both
men and women, a clearly higher RR of CVD as well as
chronic obstructive pulmonary disease (COPD) mortality
in subjects aged 51–70 years at baseline than in subjects
aged 71–90 years at baseline (Tables 3 and 4 of the paper).
In the Harvard Six Cities Study, as reanalysed by Krewski
et al. (2000), the RR for all-cause mortality in relation to an
18.6 lg/m3 increase in PM2.5 was 2.11 (0.88–5.07) for
Table 1 continued
Pollutant metric Health outcome Group RR (95 % CI) per 10 lg/m3
NO2, 24-h mean Hospital admissions, respiratory diseases, all ages A* 1.0180 (1.0115–1.0245)
CI confidence interval, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, GBD global burden of disease, HRAPIE
health risks of air pollution in Europe, MRAD minor restricted activity days, NO2 nitrogen dioxide, O3 ozone, PM2.5 particulate matter with an
aerodynamic diameter smaller than 2.5 lm, PM10 particulate matter with an aerodynamic diameter smaller than 10 lm, ppb parts per billion,
RAD restricted activity days, RR relative risk
Group A: pollutant–outcome pairs contributing to the limited set of effects but considered already accounted for by summing those with an
asterisk
Group A*: pollutant–outcome pairs contributing to the total limited set of effects (the effects are additive)
Group B: pollutant–outcome pairs contributing to the extended set of effects but considered already accounted for by summing those with an
asterisk
Group B*: pollutant–outcome pairs contributing to the total extended set of effects (the effects are additive)
Group B**: Only residual RADs to be added to total effect, after days in hospital, work days lost and days with symptoms are accounted for
a Supra-linear exponential decay saturation model (age-specific), linearized by the PM2.5 expected in 2020 under the current legislation scenario
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those\40 years old at baseline, 1.66 (1.17–2.35) for those
41–55 years old, and 1.17 (0.98–1.40) for those[55 years
old at baseline. The same reanalysis showed that, in the
ACS study, for those with high school education or less,
the RR for all-cause mortality in relation to a 24.5 lg/m3
increase in PM2.5 was 1.51 (1.00–2.27) for those\50 years
old at baseline, 1.27 (1.02–1.60) for those 50–60 years old,
and 1.28 (1.14–1.43) for those[60 years old at baseline.
Early work had already shown that impacts on life ex-
pectancy may be over-estimated when RRs observed at
certain specific ages in cohort studies are applied to sub-
jects at higher ages with high baseline mortality
(Brunekreef, 1997). Most current risk assessments assume
that the excess relative risk among adults does not vary
with age, but the GBD 2010 estimates incorporated age-
dependency of the air pollution relative risk(s) such that the
age-specific excess relative risk for cardiovascular mor-
tality declined with increasing age leading to lower
estimates of attributable burden (Lim et al. 2012; Burnett
et al. 2014).
Cessation lag between reduced long-term exposure
to PM2.5 and mortality
The distribution of the cessation lag is relevant both for the size
of the effect over a defined time period and when calculating
the economic value of the effect due to discounting the value
over time. The HRAPIE report stated that findings from the
follow-up of the Harvard Six Cities study suggest that mor-
tality effects may be partially reversible, over a time period
possibly as short as a year. Ideally, for health impact calcula-
tions, a range of possible delays between reduced exposure and
a reduced impact on mortality would be used. The HRAPIE
report noted that long-term exposure to PM2.5 is linked with
lung cancer mortality. Delays for this are likely to be measured
in decades, although lung cancer mortality is a small propor-
tion of the total. Other organizations such as the United States
Environment Protection Agency (US EPA) have recom-
mended a distribution of different lags (US EPA 2011).
Readers are referred to this and other documents (Hurley et al.
2005; COMEAP 2010) for a more detailed discussion.
Application of HRAPIE recommendations
and implications for European Union air policy
An impact assessment accompanying the EU policy pack-
age was developed by the EC and provides the results of the
implementation of the HRAPIE recommendations in a cost–
benefit context (EC 2013). According to the EC’s impact
assessment, over 406,000 premature deaths were estimated
to be related to long-term PM2.5 and short-term O3 exposure
in year 2010. New evidence on impacts from chronic O3
exposure is not included but would add around 5 % to this
total (EC 2013). The evidence of health impacts from NO2
exposure was considered, but as there was a lack of agree-
ment regarding the extent to which the exposure data used
by the EC properly reflected exposure of the population
(Holland 2014), no quantification was made of NO2 health
impacts. Further work is needed to characterize the link
between estimated NO2 exposure and health outcomes as
provided in the recommendations of the HRAPIE report.
According to the EC assessment, the mortality associ-
ated with PM, the most important pollutant, has been
reduced by around 20 % between 2000 and 2010 (EC
2013). Modelled trends in pollutant levels show that under
a business-as-usual scenario (baseline projection) the im-
pacts of air pollution will continue to decrease by 2020,
where they will amount to an estimated 340,000 premature
deaths. The progress in further reducing the health impacts
from air pollution is expected to be considerably slower
beyond 2020. On average across the EU, baseline projec-
tion suggests a decline of the loss of statistical life
expectancy attributable to the exposure to PM2.5 from
8.5 months in 2005 to 5.3 months in 2025. Depending on
the valuation methodology [Value of Statistical Life (VSL)
or Value of a Life-Year (VOLY)], the health-related ex-
ternal costs from air pollution ranged between €330 billion
and €940 billion in 2010, and would be reduced in the
baseline to €210–730 billion in 2030 (2005 € prices).
The corresponding benefits of the proposed air policy
package can be monetized, resulting in about €40–140
billion per year in 2030, while the costs of pollution
abatement to implement the package are estimated to reach
€ 3.4 billion per year in 2030. The impact assessment states
that the monetized benefits will therefore be about 12–40
times higher than the costs (EC 2013).
The policy package does not propose changes to the
existing air quality standards in the ambient air quality di-
rective at this stage. The EC acknowledges that the current
standards are insufficient for the protection of public health,
particularly in reference to the WHO air quality guidelines.
The focus will be on a full attainment of current air quality
standards by 2020. The new policy proposes stricter na-
tional emission ceilings and new source legislations which,
according to the EC, are expected to pave the way for
tightened standards in the ambient air quality directive at a
later stage. A 5-year policy review cycle is being considered
with a first review taking place no later than 2020, at which
time the scope for tightening the air quality standards will
be considered by the EC (EC 2013).
Conclusion
The scientific evidence is rapidly expanding, reaffirming
and strengthening previously reported associations as well
as revealing new health outcomes. Special efforts are
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required from the scientific community and the policy-
makers to engage in a dialogue and enable proper inter-
pretation and synthesis of the scientific evidence for use in
policy formulation. The HRAPIE project report, summa-
rized in this paper, illustrates the complexities involved in
recommending suitable CRFs, with accompanying recom-
mendations on methods, baseline rates and appropriate
strategies for combining results. These complexities need
to be acknowledged, and sufficient resources should be
made available to enable proper synthesis and interpreta-
tion of the evidence in future reviews of air pollution health
effects.
The REVIHAAP and HRAPIE projects provide scien-
tific arguments for taking decisive actions to improve air
quality to further reduce the burden of disease associated
with air pollution in Europe. They further recommend that
the EC ensures that the evidence on the health effects of air
pollutants and the implications for its air quality policy is
reviewed regularly. The material developed as part of these
projects is equally relevant to all Member States of the EU,
in their development and implementation of effective
strategies to reduce air pollution and its significant impacts
on public health. The two projects described above also
provide an important input to the development of air
quality policies by the parties of the United Nations Eco-
nomic Commission for Europe (UNECE) Convention on
Long-range Transboundary Air Pollution (LRTAP), which
are outside the EU, especially Member States from the
eastern part of the WHO European Region.
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